Developments in Pharmacy Law XXIII Sets New Attendance Record
Lane Powell Shareholder Ron Friedman was featured in the November/December 2012 issue of the American Society for Pharmacy Law (“ASPL”) Rx Ipsa Loquitur newsletter for his November 16 presentation at the ASPL Developments in Pharmacy Law XXIII seminar. At the seminar, Friedman presented on the DEA enforcement updates of 2012.
Ron Friedman reviewed government action in 2012 starting out with failure of pharmacists to exercise ‘corresponding obligation’ per the DEA. The DEA is intent on pharmacists understanding ‘red flags’ when it comes to filling controlled substances as the CVS case in Florida highlights. Some of those ‘red flags’ are out-of-state patients, and the distance traveled by patients to pain clinics, combination cocktail of benzodiazepines, muscle relaxants and opiates, questionable quantities, diagnosis on prescription, repetitive ‘prescription pattern’ by physicians, among others. Ron challenged the audience to answer, who decides what is a ‘red flag’?; when has the ‘red flag’ been sufficiently resolved?; and how will the CVS Florida decision affect other pharmacies in the U.S.? Ron contends that this decision by the DEA results in the loss of an opportunity to forge constructive relationships between distributors, pharmacies, physicians and the regulators.
View the newsletter.